
IGC Stock Forecast & Price Target
IGC Analyst Ratings
Bulls say
IGC Pharma is an early stage drug development company with a specific focus on Alzheimer's disease, which we believe presents a significant market opportunity. The company recently reported positive interim results for its Phase 2 trial for IGC-AD1, and we expect additional positive data and milestone progress to be catalysts for the stock. However, there are risks to our outlook, including balance sheet/liquidity risks, product failure in clinical trials, and regulatory and commercialization hurdles.
Bears say
IGC Pharma is a clinical-stage pharmaceutical company with a primary focus on developing cannabinoid-based formulations for various diseases and conditions, including Alzheimer's disease. Despite the positive interim results from their Phase 2 trial and upcoming milestones, the company's small revenue and recent change in fiscal year end raise concerns about their financial stability. Additionally, while their investigational drug IGC-AD1 has shown promise in preclinical studies, there is still a need for more rigorous clinical trials before it can be considered an effective treatment for Alzheimer's disease.
This aggregate rating is based on analysts' research of India Globalization Capital and is not a guaranteed prediction by Public.com or investment advice.
IGC Analyst Forecast & Price Prediction
Start investing in IGC
Order type
Buy in
Order amount
Est. shares
0 shares